Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from LLY

Eli Lilly (LLY) Faces Bearish Options Flow, But Probabilities Tell a Different Story

Options traders leaned bearish on LLY stock, but market demand data reveals conditional odds that may support near-term upside.

A $1.3 Billion Reason to Buy Eli Lilly Stock Now

A $1.3 Billion Reason to Buy Eli Lilly Stock Now

Eli Lilly has just acquired gene-editing company Verve Therapeutics.

Could Meta and Eli Lilly Trigger the Next Stock Split Boom?

Could Meta and Eli Lilly Trigger the Next Stock Split Boom?

Meta Platforms and Eli Lilly are two stocks that could perform stock splits down the road, and it's not just because of their high share prices.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Eli Lilly vs. Novo Nordisk: Which Stock Is the Winner of the Weight-Loss Drug Boom?

Both companies have established a solid presence in the weight-loss drug market, but only one of them can lead.

Eli Lilly : A Breakout Biotech Powerhouse With Room to Run

Eli Lilly's growth is fueled by leading drug sales and a promising pipeline, suggesting a sustained upward trajectory for the pharmaceutical innovator.

Is Eli Lilly and Company Stock Underperforming the Dow?

While Eli Lilly has underperformed the Dow over the past year, analysts remain bullish about the stock’s prospects.

3 Trades Members of Congress Are Making Right Now

Knowing what Congressional leaders are buying can give investors insight into future legislation that could benefit these companies

inkl

Read news from The Economist, FT, and more,
with one subscription

This Pharma Stock Is Still a ‘Strong Buy’ Despite Trump’s Plans to Lower Drug Prices

This Pharma Stock Is Still a ‘Strong Buy’ Despite Trump’s Plans to Lower Drug Prices

Despite Trump’s executive order to cut drug prices, Eli Lilly’s stock surged, showing strong resilience and impressive gains amidst regulatory concerns.

Are Wall Street Analysts Bullish on Eli Lilly Stock?

Are Wall Street Analysts Bullish on Eli Lilly Stock?

Despite lagging behind the broader market over the past year, Eli Lilly continues to enjoy a highly bullish outlook from Wall Street analysts, who remain confident in the company’s long-term growth potential.

Is Eli Lilly a Buy After Weak Earnings and CVS-Novo Partnership?

Is Eli Lilly a Buy After Weak Earnings and CVS-Novo Partnership?

Shares of Eli Lilly just got walloped. So, is the company still the name to own in GLP-1s, or are the tables turning on this pharma giant?

Eli Lilly Nails Oral GLP-1 Trial—Here’s What It Means for LLY

Eli Lilly Nails Oral GLP-1 Trial—Here’s What It Means for LLY

Take a deep dive into Eli Lilly's latest clinical GLP-1 results that sent shares soaring. The company has a big opportunity to serve needle-phobic patients.

Eli Lilly's Quarterly Earnings Preview: What You Need to Know

Eli Lilly's Quarterly Earnings Preview: What You Need to Know

Eli Lilly is scheduled to report its first-quarter results next month, and analysts expect a significant double-digit earnings growth.

Analysts Love These 2 Stocks to Buy for Q2

Analysts Love These 2 Stocks to Buy for Q2

Investors could snag these two stocks as BofA flags the companies as well-positioned winners in an uncertain quarter.

Is Eli Lilly Stock Outperforming the Nasdaq?

Is Eli Lilly Stock Outperforming the Nasdaq?

Eli Lilly has outperformed the Nasdaq over the past year, and analysts are highly optimistic about the stock’s prospects.

Get all your
news in one place.

100's of premium titles.
One news app.

Regeneron: Is It the Perfect Biotech Stock for Value and Growth?

Regeneron is trading at historically low valuations as its Dupixent blockbuster drug could get a 30% increase in TAM if the FDA approves its use in COPD.

3 Pharmaceutical Stocks Betting Big on Weight Loss Drugs

Weight-loss drugs aren’t just slimming waists; they create a $100 billion market opportunity. With plenty up for grabs, pharmaceutical giants like Eli Lilly and Company (LLY), Novo Nordisk (NVO), and Amgen (AMGN) are betting big on next-generation weight loss treatments to dominate this booming market. Keeping reading.

MarketBeat Week in Review – 02/10 - 02/14

Despite many negative headlines, stocks are trading near all-time highs; next week will be a shortened trading week, with most of the monthly economic data in

Will Eli Lilly Stock Keep Climbing? Q2 Trial Results Are Crucial

Eli Lilly is still seeing rapid sales growth for its diabetes and weight loss drugs. However, one drug waiting in the wings hopes to be its next blockbuster.

Get all your
news in one place.

100's of premium titles.
One news app.

These Stocks Missed on Earnings, But Will Rebound Next Quarter

Here are three stocks from companies that missed on earnings but have strong support from analysts that makes each stock a solid Buy for the next year

What Are Wall Street Analysts' Target Price for Eli Lilly Stock?

As Eli Lilly has outperformed the broader market over the past year, Wall Street analysts maintain a bullish outlook on the stock’s prospects.

Eli Lilly Stock Rises After Profit, Outlook Top Expectations

Eli Lilly stock is higher Thursday after the pharma giant beat fourth-quarter profit expectations and issued strong 2025 guidance. Here's what you need to know.

Stocks Muted Before the Open With Focus on U.S. Economic Data and Amazon Earnings

March S&P 500 E-Mini futures (ESH25) are up +0.05%, and March Nasdaq 100 E-Mini futures (NQH25) are down -0.08% this morning as investors awaited a new round of U.S. economic data, remarks from Federal Reserve officials, and an earnings report from “Magnificent Seven” member Amazon.

What Does the Future Hold for Eli Lilly?

Eli Lilly's two major GLP-1 drugs have dominated headlines, but a slate of new treatments in development—and some already available—suggest a bright future.

Stock Market Today: Stocks Are Mixed Ahead of CPI

Cool wholesale inflation numbers provide only slight relief before Wednesday's release of December Consumer Price Index data.

Eli Lilly: 4 Reasons Investors Shouldn’t Miss This Opportunity

Eli Lilly shares are down 17.7% from its highs. The company posted 128% YoY revenue jump in its Mounjaro GLP-1/GIP treatment with no signs of slowing down.

1 … 7 8 9 10

People

213,132 stories

Marjorie Taylor Greene

Gabriel OsorioMazilli

Ania Jastreboff

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

US Federal Reserve

Amazon.com Inc.

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Executive Order

Places

417,892 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play